These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25360237)

  • 1. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.
    Ai J; Tiu RV
    Ther Adv Hematol; 2014 Aug; 5(4):107-20. PubMed ID: 25360237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
    Tabarestani S; Movafagh A
    Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
    Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
    Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
    Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.
    Amarante-Mendes GP; Rana A; Datoguia TS; Hamerschlak N; Brumatti G
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant
    Lu L; Kok CH; Saunders VA; Wang J; McLean JA; Hughes TP; White DL
    Oncotarget; 2018 Oct; 9(78):34735-34747. PubMed ID: 30410673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2024 Aug; ():. PubMed ID: 39093014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia.
    Tiribelli M; Eskazan AE
    Oncol Ther; 2019 Dec; 7(2):95-100. PubMed ID: 32699984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
    Lau A; Seiter K
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
    McCarron SL; O'Connor LM; Langabeer SE; Conneally E
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
    Terasawa T; Dahabreh I; Trikalinos TA
    PLoS Curr; 2010 Dec; 2():RRN1204. PubMed ID: 21188137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
    Soverini S; de Benedittis C; Mancini M; Martinelli G
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
    Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH
    Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
    Khoury HJ; Bixby DL
    Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
    Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.